KBC Group
PCRX icon

KBC Group’s Pacira BioSciences PCRX Stock Holding History

KBC Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,439
Closed -$41K – 1846
2024
Q2 		$41K Hold
1,439
– – ﹤0.01% 1718
2024
Q1 		$42K Hold
1,439
– – ﹤0.01% 1643
2023
Q4 		$49K Hold
1,439
– – ﹤0.01% 1548
2023
Q3 		$44K Sell
1,439
-2,226
-61% -$80.2K ﹤0.01% 1555
2023
Q2 		$147K Sell
3,665
-187
-5% -$7.73K ﹤0.01% 1047
2023
Q1 		$157K Hold
3,852
– – ﹤0.01% 1055
2022
Q4 		$149K Hold
3,852
– – ﹤0.01% 1070
2022
Q3 		$205K Hold
3,852
– – ﹤0.01% 958
2022
Q2 		$225K Buy
3,852
+2,235
+138% +$146K ﹤0.01% 951
2022
Q1 		$123K Hold
1,617
– – ﹤0.01% 1131
2021
Q4 		$97K Hold
1,617
– – ﹤0.01% 1184
2021
Q3 		$91K Hold
1,617
– – ﹤0.01% 1182
2021
Q2 		$98K Hold
1,617
– – ﹤0.01% 1175
2021
Q1 		$113K Hold
1,617
– – ﹤0.01% 1164
2020
Q4 		$97K Hold
1,617
– – ﹤0.01% 1164
2020
Q3 		$97K Buy
+1,617
New +$94K ﹤0.01% 1122
2017
Q1 		– Sell
-2,201
Closed -$71K – 1321
2016
Q4 		$71K Sell
2,201
-43,454
-95% -$1.45M ﹤0.01% 1269
2016
Q3 		$1.56M Buy
45,655
+45,144
+8,834% +$1.77M 0.02% 634
2016
Q2 		$17K Sell
511
-11,025
-96% -$542K ﹤0.01% 1258
2016
Q1 		$611K Sell
11,536
-16,488
-59% -$964K 0.01% 786
2015
Q4 		$2.15M Buy
28,024
+27,018
+2,686% +$1.53M 0.04% 453
2015
Q3 		$41K Sell
1,006
-2,021
-67% -$124K ﹤0.01% 1252
2015
Q2 		$214K Sell
3,027
-39,302
-93% -$3.1M ﹤0.01% 1112
2015
Q1 		$3.76M Buy
42,329
+14,159
+50% +$1.44M 0.05% 376
2014
Q4 		$2.5M Buy
28,170
+20,936
+289% +$1.98M 0.03% 527
2014
Q3 		$701K Sell
7,234
-39,512
-85% -$3.84M 0.02% 643
2014
Q2 		$4.29M Buy
46,746
+11,726
+33% +$893K 0.05% 412
2014
Q1 		$2.45M Buy
+35,020
New +$2.38M 0.04% 444

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

KBC Group's PCRX Position: Q3 2024 in Review

KBC Group sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 1,439 shares — an estimated $41K sold.

KBC Group first reported a position in PCRX in Q1 2014 and held it in 28 quarters. The position peaked at $4.29M in Q2 2014. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • KBC Group reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • KBC Group sold 1,439 Pacira BioSciences shares in Q3 2024, an estimated $41K.
  • KBC Group first reported a position in Pacira BioSciences in Q1 2014 and held it in 28 quarters.
  • KBC Group's Pacira BioSciences position peaked at $4.29M in Q2 2014.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on KBC Group's 13F filing for Q3 2024, filed 6 Nov 2024.